In a collaboration between the partner sites Heidelberg and Dresden of the National Center for Tumor Diseases (NCT) a blood extracellular-vesicle-transported mRNA signature to discriminate high risk pancreatic cancers patients and predict overall survival time of the tumor carrying individual was identified. We were fortunate to collaborate.   See the paper published in J Hematol & Oncology.

As part of the NEURO-ONCOLOGY WORKING GROUP (NOA) in the German Cancer Association (DKG) we had the pleasure of moderating a webinar on fundamentals, current trends and clinical perspectives with internationally renowned key opinion makers in this exciting new field of research. See the program.

MET F/SVs but not genomic amplification, were highly enriched in the secondary glioblastomas (sGBM) and marked worse prognosis. Further molecular and scRNA-seq analysis revealed that MET F/SVs were induced in the course of glioma evolution and highly associated with MET overexpression. Subsequent in vitro and the clinical study showed that cells and patients harboring MET F/SVs have better response to MET inhibitors. See the paper.

Accreditation approved to participate in European network on 3R – Replace, Refine, Reduce animal research. Excited to participate in WG1 on “Quality and Translatability of Science”.

MET F/SVs but not genomic amplification, were highly enriched in the secondary glioblastomas (sGBM) and marked worse prognosis.